Skip to main content
Digital Environment Research Institute (DERI)

Sosei Heptares

The three companies in the AIDD Doctoral Training Programme are united by their interest in the development of transformative AI technologies for delivering new bioscience discoveries underpinning drug discovery.
— Dr Chris de Graaf, Director of Computational Chemistry at Sosei Heptares Therapeutics Ltd.

Sosei Heptares is a research-focused biotechnology group, publicly listed in Japan and with sites in Tokyo, London, and Cambridge (UK). Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design, and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform. Sosei Heptares’ primary focus is the discovery and early development of new medicines originating from our proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities.

The company is advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation, and other rare/specialty indications. We have established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies.

Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK. Sosei Heptares has approximately 160 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.

For more information please click to access us on Twitter, Linkedin, or visit our website.




Back to top